Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.
You may also be interested in...
The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also to support many initiatives in last year's budget request.
US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.